The evaluation of ovarian reserve after uterine artery embolization

A comparative study of ovarian reserve after uterine artery embolization and hysterectomy for uterine fibroma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202163461N5

Enrollment

Registered

2012-05-05

Start date

2012-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uerine fibroma and bleeding. ????????? ??????? ???

Interventions

Treatment - Surgery

Intervention 1: Embolization: Record of patient demographic data . The evaluation of FSH level in third day of cycle before intervention. The evaluation of Hb level before intervention. The eval

Embolization: Record of patient demographic data . The evaluation of FSH level in third day of cycle before intervention. The evaluation of Hb level before intervention. The evaluation of ??

Hysterectomy: Record of patient demographic data . The evaluation of FSH level in third day of cycle before intervention. The evaluation of Hb level before intervention. The evaluation of ??

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 25-45, sever vaginal bleeding , 16 week mass, anemia and pressure effect caused by uterine fibroma. exclusion criteria: pelvic malignancy, ovarian patology,pelvic infection,substance media sensitivity.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FSH level. Timepoint: Third day of month before and third day six month after both procedures. Method of measurement: serum level , mIU/ cc.	—

Secondary

Measure	Time frame
Number of dominant follicle between 12-14 days of cycle. Timepoint: Before and 6 month after intervention. Method of measurement: One dominant follicle by sonography.;Hb level. Timepoint: Before and 6 month after intervention. Method of measurement: Blood level.;Duration of hospitalization. Timepoint: hospitalization time. Method of measurement: The number of days hospitalization through intervention.;Time required to return normal activity. Timepoint: The number of weeks to return normal activity. Method of measurement: weeks.;Pain level after intervention. Timepoint: one week after intervention. Method of measurement: 1-10 score.;Cost of procedure. Timepoint: cost of hospitalization and. Method of measurement: Rials.;Repeat intervention. Timepoint: By 6 month after first intervention. Method of measurement: Operation and hormonal drugs.;Patients symptoms. Timepoint: 6 month after intervention. Method of measurement: Hot flash, bleeding,pain,.	—

Measure

Time frame

Number of dominant follicle between 12-14 days of cycle. Timepoint: Before and 6 month after intervention. Method of measurement: One dominant follicle by sonography.;Hb level. Timepoint: Before and 6 month after intervention. Method of measurement: Blood level.;Duration of hospitalization. Timepoint: hospitalization time. Method of measurement: The number of days hospitalization through intervention.;Time required to return normal activity. Timepoint: The number of weeks to return normal activity. Method of measurement: weeks.;Pain level after intervention. Timepoint: one week after intervention. Method of measurement: 1-10 score.;Cost of procedure. Timepoint: cost of hospitalization and. Method of measurement: Rials.;Repeat intervention. Timepoint: By 6 month after first intervention. Method of measurement: Operation and hormonal drugs.;Patients symptoms. Timepoint: 6 month after intervention. Method of measurement: Hot flash, bleeding,pain,.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfiroozeh veisi

Kermanshah University of Medical Sciences,Kermanshah,Iran

firoozehveisi@yaho.com+98 83 1427 6309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026